Pharmaceutical Supply Chains: Is the Talent Brief Keeping Pace with the Risk?
Written by Charlotte Whitehouse
Over recent months, Supply Chain and Logistics has been the fastest-growing area of pharmaceutical hiring activity coming into Practicus.
That doesn’t necessarily indicate a market-wide hiring boom. What’s more interesting is how the requirements are changing.
Businesses aren’t simply looking for people to manage inventory, logistics and suppliers. Increasingly, they need individuals who can see risk across complex networks, bring different functions together and help the organisation respond when established plans no longer work.
Given rising geopolitical tensions, tariffs, regulatory change and continued disruption to international trade, there are plenty of reasons why those plans may need to change.
When Geopolitical Risk Becomes Operational Reality
Tariffs, conflict, shipping disruption and changing international relationships are no longer remote geopolitical issues. They can directly affect the availability and cost of active pharmaceutical ingredients, packaging, medical devices and other critical materials. A political decision in one market can quickly become a manufacturing problem in another, and potentially a patient-supply issue somewhere else entirely.
At the same time, governments are placing greater emphasis on domestic and regional manufacturing, diversified sourcing and the security of critical medicines.
For years, many supply chains were reasonably designed around efficiency: consolidated suppliers, outsourced operations, lean inventory and just-in-time delivery. However, the external environment has changed.
The question for pharmaceutical companies is whether the model that appears most efficient under normal conditions provides enough flexibility when those conditions suddenly move.
Visibility Doesn’t Always Mean Resilience
Many organisations have good oversight of their immediate suppliers, contract manufacturers and logistics partners. The greater vulnerability can sit further down the chain. Two approved suppliers may appear to provide diversification while relying on the same manufacturer, raw material, shipping route or geography.
Similarly, outsourcing parts of an operation to a 3PL, 4PL, CDMO or other specialist provider may simplify internal delivery, but it doesn’t remove the pharmaceutical company’s accountability for quality, continuity and ultimately patient supply.
We have seen this within a longstanding Japanese pharmaceutical client of ours, where we’ve supported appointments focused on operational logistics and distribution across Europe. These roles have included oversight of 3PL performance, customs and trade compliance, and GDP/GMP requirements.
In practice, resilience doesn’t come from a slide deck. It comes from maintaining day-to-day operational control across external partners and every handover in the process.
This creates some important questions:
- How far into the supplier network does the business genuinely have visibility?
- Which products or materials depend on a single geography?
- How quickly could alternative suppliers be qualified?
- Who has the authority to accept additional cost in return for greater resilience?
- Are contingency plans regularly tested or simply documented?
What Does Agility Really Look Like?
“Agility” is used frequently in conversations about Supply Chain, but it can become meaningless unless it changes how decisions are made.
An agile organisation doesn’t necessarily manufacture everything locally, hold excessive inventory or duplicate every supplier. Those approaches can create considerable cost without guaranteeing resilience. Instead, agility means understanding where the greatest vulnerabilities genuinely sit and making deliberate choices around them. That could include pre-qualified alternative suppliers, regional manufacturing and distribution options, strategic stock for critical products, better data across external partners and scenario plans that have been tested before they are needed.
Most importantly, it requires Supply Chain, Quality, Regulatory, Finance and Commercial to make decisions together.
We have seen the importance of this cross-functional approach through technical and packaging-change activity for our longstanding Japanese pharmaceutical client. We’ve placed interim specialists to support CMO transfers and technical operations, as well as coordinating artwork and packaging changes across multiple markets.
These assignments sit at the intersection of Quality, Regulatory and Supply Chain. When those functions move out of sync, resilience can quickly become a product-release and continuity risk.
A business may have alternative options on paper, but if it takes several months to approve and implement them, its supply chain isn’t genuinely agile.
The Changing Talent Requirement
This helps explain the change we’re seeing in Supply Chain appointments.
Recent assignments have required much more than traditional logistics or planning experience. Clients need people who can manage complex external partners, operate within regulated environments, support launches and technology transfers, challenge existing operating models and communicate risk effectively to senior leadership.
The strongest Supply Chain leaders increasingly combine operational knowledge with commercial judgement, regulatory awareness, data literacy and the confidence to influence across functions.
In some cases, the answer has been a permanent appointment. In others, organisations have brought in interim expertise to manage a particular transfer, disruption or transformation while deciding what capability they need for the longer term. However, there can be a disconnect.
Businesses often say they want strategic and agile Supply Chain leadership while continuing to recruit against job descriptions designed primarily to operate the existing model.
If the brief focuses almost entirely on delivering today’s process, who is responsible for challenging whether that process remains appropriate for tomorrow?
Scaling into New
The same challenge becomes particularly visible when businesses expand internationally.
In our work with a US-based aesthetics company, we’ve seen how quickly international growth turns Supply Chain into an enterprise-wide delivery challenge. One assignment focused on expansion into new countries while maintaining close operational alignment with the US headquarters. This included demand-planning rhythms, lead times and the practical realities of physical product flow as new markets came online.
It reinforced a broader point: resilience isn’t owned by Logistics alone. It depends on how Commercial, Finance, Regulatory, Quality and Supply Chain make decisions together when timelines are fixed and the trade-offs are real.
The Real Test of Resilience
Not every disruption can be predicted, and building resilience cannot mean preparing equally for every conceivable scenario. The more practical objective is to create an organisation capable of responding intelligently when circumstances change. That requires more than additional suppliers, technology or inventory. It requires genuine visibility, faster cross-functional decision-making and people with the authority to act before an operational concern becomes a patient-supply problem.
Pharmaceutical businesses are increasingly asking whether their supply chains are resilient enough for a less predictable world.
Perhaps the more revealing question is whether their organisations (and the leadership capability within them) are ready to adapt.
Let’s continue the conversation!
ABOUT PRACTICUS
You can find out more about us on the about us page
Check out our latest insights here:
- Water Infrastructure Investment: Why the Sector Is Still Playing Catch-Up
- HR Roundtable: The People Challenges Shaping Pharma and Life Sciences Right Now
- How to Reduce Time to Hire Without Sacrificing Quality
- How Dr Google Is Changing the Way We Seek Healthcare
- Driving Change: Tackling Public Sector Recruitment Challenges